Adhesion molecules: opportunities for modulation and a paradigm for novel therapeutic approaches in cancer

Bibliography

• TAKEICHI M: Cadherin cell adhesion receptors as a morphogenetic regulator. Science (1991) 251:1451–1455.
   PubMed Web of Science ®Google Scholar
• HYNES RO: Integrins: versatility, modulation, and sig-nalling in cell adhesion. Cell (1992) 69:11–25.
   PubMed Web of Science ®Google Scholar
• SPRINGER TA: Adhesion receptors of the immune sys-tem. Nature (1990) 346:425–434.
   PubMed Web of Science ®Google Scholar
• ALBELDA SM, BUCK CA: Integrins and other cell adhe-sion molecules. FASEBJ (1990) 4:2868–2880.
   PubMed Web of Science ®Google Scholar
• EAST JA, HART IR: CD44 and its role in tumour progres-sion and metastasis. Eur. J. Cancer (1993) 14:1921–1922.
   Google Scholar
• TAKEICHI M: Functional correlation between cell adhe-sive properties and some cell surface proteins. J. Cell Biol. (1977) 75: 464–474.
   PubMed Web of Science ®Google Scholar
• CEPEK KL, SHAW SK, PARKER CM et al.: Adhesion betweenepithelial cells and T lymphocytes mediated by E-cad-herin and the alpha E beta 7 integrin. Nature (1994) 372:190–193.
   PubMed Web of Science ®Google Scholar
• KARECLA PI, BOWDEN SJ, GREEN SJ, KILSHAW PJ: Recog-nition of E-cadherin on epithelial cells by the mucosal T cell integrin alpha M290 beta 7 (alpha E beta 7). Eur. Immunol. (1995) 25:852–856.
   PubMed Web of Science ®Google Scholar
• PIALI L, HAMMEL P, UHEREK C eta': CD31/PECAM-1 is aligand for alpha v beta 3 integrin involved in adhesion of leukocytes to endothelium. J. Cell Biol. (1995) 130:451–460.
   PubMed Web of Science ®Google Scholar
• CARTER WG, WAYNER EA, BOUCHARD TS, KAUR P: Therole of integrins alpha 2 beta 1 and alpha 3 beta 1 in cell-cell and cell-substrate adhesion of human epider-mal cells. Cell Biol. (1990) 110:1387–1404.
   PubMed Web of Science ®Google Scholar
• BARSKY SH, SIEGAL GP, JANNOTTA F, LIOTTA LA: Loss ofbasement membrane components by invasive tumours but not by their benign counterparts. Lab. Invest. (1983) 49:140–147.
   PubMed Web of Science ®Google Scholar
• BEHRENS J, FRIXEN U, SCHIPPER J, VVEIDNER M, BIRCH-METER W: Cell adhesion in invasion and metastasis. Semin. Cell Biol. (1992) 3:169–178.
   PubMedGoogle Scholar
• RAO CN, MARGULIES IMK, TRALKA S et al.: Isolation of asubunit of laminin and its role in molecular structure and tumour cell attachment. J. Biol. Chem. (1982) 257:9740–9744.
   PubMed Web of Science ®Google Scholar
• STETLER-STEVENSON WG, AZNAVOORIAN S, LIOTTA LA:Tumour cell interactions with the extracellular matrix during invasion and metastasis. Ann. Rev. Cell Biol. (1993) 9:541–573.
   PubMed Web of Science ®Google Scholar
• RAY JM, STETLER-STEVENSON WG: The role of matrixmetalloproteinases and their inhibitors in tumour in-vasion, metastasis and angiogenesis. Eur. Resp. 1 (1994) 7:2062-2072.
   Google Scholar
• BLAST F: Urokinase and urokinase receptor: a parac-rine/autocrine system regulating cell migration and invasiveness. Bioassays (1993) 15:105–111.
   PubMed Web of Science ®Google Scholar
• JONES PA, DECLERCK YA: Extracellular matrix destruc-tion by invasive tumour cells. Cancer Metast. Rev. (1982) 1:289–317.
   PubMedGoogle Scholar
• MEISSAUER A, KRAMER MD, SCHIRRMACHER V, BRUNNER G: Generation of cell surface-bound plasmin by cell-as-sociated urokinase-type or secreted tissue-type plasmi-nogen activator: a key event in melanoma cell invasiveness in vitro. Exp. Cell Res. (1992) 199:179–190.
   PubMed Web of Science ®Google Scholar
• SPYRATOS F, MAUDELONDE T, BROUILLET JP et al.: Cathepsin D. An independent prognostic factor for metastasis of breast cancer. Lancet (1992) 2(8672):1115–1118.
   Google Scholar
• STOKER M, GHERARDI E: Scatter factor is a fibroblast-de-rived modulator of epithelial cell mobility. Nature (1987) 327:239–242.
   PubMed Web of Science ®Google Scholar
• GHERARDI E: Growth factors and cell movements. Eur. J. Cancer (1991) 27:403–405.
   PubMed Web of Science ®Google Scholar
• DENEKAMP J, HILL S: Angiogenic attack as a therapeutic strategy for cancer. Radiother. Oncol (1991) 20\(Suppl. 1):103–112.
   Google Scholar
• LIOTTA LA, STEEG PS, STETLER-STEVENSON WG: Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell (1991) 64:327–336.
   PubMed Web of Science ®Google Scholar
• FOLKMAN J, SHING Y: Angiogenesis. J Biol Chem. (1992) 267:10931–10934.
   PubMed Web of Science ®Google Scholar
• ELLIS LM, FIDLER IJ: Angiogenesis and metastasis. Eur. J. Cancer (1996) 32A:2451–2460.
   PubMed Web of Science ®Google Scholar
• KEMLER R: Classical cadherins. Semin. Cell Biol. (1992) 3:149–155.
   PubMedGoogle Scholar
• NAGAFUCHI A, ISHIHARA S, TSUKITA S: The roles of catenins in the cadherin-mediated cell adhesion: func-tional analysis of E-cadherin-alpha catenin fusion molecules. J. Cell Biol. (1994) 127:235–245.
   PubMed Web of Science ®Google Scholar
• OZAWA M, BARIBAULT H, KEMLER R: The cytoplasmic domain of the cell adhesion molecule uvomorulin as-sociates with three independent proteins structurally related in different species. EMBO J (1989) 8:1711–1717.
   PubMed Web of Science ®Google Scholar
• REYNOLDS AB, DANIEL J, MCCREA PD et al.: Identification of a new catenin: the tyrosine kinase substrate p120cas associates with E-cadherin complexes. Mol Cell Biol. (1994) 14:8333–8342.
   PubMed Web of Science ®Google Scholar
• EDELMAN GM: Adhesion and counteradhesion: mor-phogenetic functions of the cell surface. Prog Brain Res (1994) 101:1–14.
   PubMed Web of Science ®Google Scholar
• TAKEICHI M: Cadherins in cancer: implications for invasion and metastasis. Curr. Opin. Cell Biol (1993) 5:806–811.
   PubMed Web of Science ®Google Scholar
• BEHRENS J, MAREEL MM, VAN ROY FM, BIRCHMEIER W:Epithelial cells acquire invasive propeties after the loss of uvomorulin-mediated cell-cell adhesion. J. Cell Biol. (1989) 108:2435–2447.
   PubMed Web of Science ®Google Scholar
• WATABE M, NAGAFUCHI A, TSUKITA S, TAKEICHI M: Induction of polarized cell-cell association and retarda-tion of growth by activation of the E-cadherin-catenin adhesion system in a dispersed carcinoma line. J. Cell Biol (1994) 127:247–256.
   PubMed Web of Science ®Google Scholar
• LIU D, NIGAM AK, LALANI E-N, STAMP GWH, PIGNATELLI M: Transfection of E-cadherin into a human colon carcinoma cell line induces differentiation and inhibits growth in vitro. Gut (1993) 34:27.
   Google Scholar
• WILDING J, VOUSDEN KH, SOUTTER WP et al.: E-cadherin transfection down-regulates the epidermal growth fac-tor receptor and reverses the invasive phenotype of human papilloma virus-transfected keratinocytes. Can-cer Res. (1996) 56:5285–5292.
   Google Scholar
• DORUDI S, HANBY AM, POULSOMR, NORTHOVER J, HART IR: Level of expression of E-cadherin mRNA in colorec- tal cancer correlates with clinical outcome. Br. J. Cancer (1995) 71:614–616.
   PubMed Web of Science ®Google Scholar
• UMBAS R, ISAACS VVB, BRINGUIER PP et al.: Decreased E-cadherin expression is associated with poor progno- sis in patients with prostate cancer. Cancer Res (1994) 54:3929–3933.
   PubMed Web of Science ®Google Scholar
• OKA H, SHIOZAKI H, KOBAYASHI K et al Expression of E-cadherin cell adhesion molecules in human breast cancer tissues and its relationship to metastasis. Cancer Res (1993) 53: 1696–1701.
   PubMed Web of Science ®Google Scholar
• MOLL R, MITZE M, FRIXEN UH, BIRCHMEIER W: Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas. Am J. Pathol. (1993) 143:1731–1742.
   PubMed Web of Science ®Google Scholar
• BRINGUIER PP, UMBAS R, SCHAAFSMA HE et al.: De- creased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors. Cancer Res. (1993) 53:3241–3245.
   PubMed Web of Science ®Google Scholar
• LIPPONEN PK, ESKELINEN MJ: Reduced expression of E-cadherin is related to invasive disease and frequent recurrence in bladder cancer. J. Cancer Res. Clin. Oncol. (1995) 121:303–308.
   PubMed Web of Science ®Google Scholar
• PIGNATELLI M, ANSARI TW, GUNTER P et al.: Loss of membranous E-cadherin expression in pancreatic can-cer: correlation with lymph node metastasis, high grade, and advanced stage. J. Pathol (1994) 174:243–248.
   PubMed Web of Science ®Google Scholar
• JANKOWSKI JA, NEWHAM PM, KANDEMIR O et al: Differ- ential expression of E-cadherin in normal, metaplastic and dysplas tic oesophageal mucosa: a putative biomarker. Int.J. Oncol (1994) 4:441–448.
   PubMed Web of Science ®Google Scholar
• MAYER B, JOHNSON JP, LEITL F et al: E-cadherin expres- sion in primary and metastatic gastric cancer: down-regulation correlates with cellular dedifferentiation and glandular disintegration. Cancer Res. (1993) 53:1690–1695.
   PubMed Web of Science ®Google Scholar
• SCHIPPER JH, FRIXFN UH, BEHRENS J et al E-cadherin expression in squamous cell carcinomas of head and neck: inverse correlation with tumor dedifferentiation and lymph node metastasis. Cancer Res. (1991) 51:6328–6337.
   PubMed Web of Science ®Google Scholar
• VESSEY CJ, WILDING J, FOLARIN N et al: Altered expres- sion and function of E-cadherin in cervical intraepi-thelial neoplasia and invasive squamous cell carcinoma. J. Pathol. (1995) 176:151–159.
   PubMed Web of Science ®Google Scholar
• GAGLIARDI G, KANDEMIR O, LIU D et al.: Changes in E-cadherin immunoreactivity in the adenoma-carci- noma sequence of the large bowel. Virchows Arch. (1995) 426:149–154.
   PubMed Web of Science ®Google Scholar
• VALIZADEH A, KARAYIANNKIS AJ, EL-HARIRY I, KMIOT W, PIGNATELLI M: Expression of E-cadherin-associated molecules (a-,y-catenins and p120) in colorectal polyps. Am. J. Pathol (1997) 150:1977–1983.
   PubMed Web of Science ®Google Scholar
• CARTER BS, EWING CM, WARD WS: Allelic loss of chro- mosomes 16q and 10q in human prostate cancer. Proc. Natl. Acad. Sci. USA (1990) 87:8751–8755.
   PubMed Web of Science ®Google Scholar
• GRAFF JR, HERMAN JG, LAPIDUS RG et al.: E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res. (1995) 55:5195–5199.
   PubMed Web of Science ®Google Scholar
• YOSHIURA K, KANAI Y, OCHIAI A et al: Silencing of the E-cadherin invasion-suppressor gene by CpG methyla- tion in human carcinomas. Proc. Natl. Acad. Sci. USA (1995) 92:7416–7419.
   PubMed Web of Science ®Google Scholar
• KADOWAKI T, SHIOZAKI H, INOUE M et al.: E-cadherin and alpha-catenin expression in human esophageal cancer. Cancer Res (1994) 54:291–296.
   PubMed Web of Science ®Google Scholar
• SHIMAZUI T, SCHALKEN JA, GIROLDI LA et al: Prognostic value of cadherin-associated molecules (alpha-, beta-, and gamma-catenins and p120cas) in bladder tumors. Cancer Res. (1996) 56:4154–4158.
   PubMed Web of Science ®Google Scholar
• DEDHAR S: Integrin mediated signal transduction in oncogenesis: an overview. Cancer Metast. Rev. (1995) 14:165–172.
   PubMed Web of Science ®Google Scholar
• CLARK EA, BRUGGE JS: Integrins and signal transduction pathways: the road taken. Science (1995) 268:233–239.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ MA, SCHALLER MD, GINSBERG MH: Integrins: emerging paradigms of signal transduction. Ann. Rev. Cell Biol. Dev. Biol (1995) 11:549–600.
   PubMed Web of Science ®Google Scholar
• RUOSLAHTI E, OBRINK B: Common principles in cell adhesion. Exp. Cell Res. (1996) 227:1–11.
   PubMed Web of Science ®Google Scholar
• PIERSCHBACHER MD, RUOSLAHTI E: Influence of stereo- chemistry of the sequence Arg-Gly-Asp-Xxx on binding specificity in cell adhesion. J. Biol. Chem. (1987) 262:17294–17298.
   PubMed Web of Science ®Google Scholar
• BAJT ML, LOFTUS JC: Mutation of a ligand binding domain of 133 integrin. J. Biol. Chem. (1994) 269:20913–20919.
   PubMed Web of Science ®Google Scholar
• DEDHAR S, HANNIGAN GE: Integrin cytoplasmic inter- actions and bidirectional transmembrane signalling. Curr. Opin. Cell Biol (1996) 8:657–669.
   PubMed Web of Science ®Google Scholar
• YAMADA KM, MIYAMOTO S: Integrin transmembrane signalling and cytoskeletal control. Curr. Opin. Cell Biol. (1995) 7:681–689.
   PubMed Web of Science ®Google Scholar
• O'TOOLE TE, KATAGIRI Y, FAULL RJ et al.: Integrin cyto- plasmic domains mediate ins ide-out transduction. J. Cell Biol (1994) 124:1047–1059.
   Google Scholar
• ALBELDA SM, METTE SA, ELDER DE et al: Integrin distribution in malignant melanoma: association of the P3 subunit with tumour progression. Cancer Res. (1990) 50:6757–6764.
   PubMed Web of Science ®Google Scholar
• VAN DUINEN CM, VAN DEN BROEK LJ, VERMEER BJ, FLEUREN GJ, BRUIJN JA: The distribution of cellular adhesion molecules in pigmented skin lesions. Cancer (1994) 73:2131–2139.
   PubMed Web of Science ®Google Scholar
• DANEN EH, VAN MUIJEN GN, RUITER DJ: Role of integrins as signal transducing cell adhesion molecules in human cutaneous melanoma. Cancer Surv. (1995) 24:43–65.
   PubMedGoogle Scholar
• BARTOLAZZI A, CERBONI C, NICOTRA MR et al: Transfor- mation and tumour progression are frequently associ-ated with expression of the alpha3/betal heterodimer in solid tumours. Int. J. Cancer (1994) 58:488–491.
   PubMed Web of Science ®Google Scholar
• VAN WAES C, CAREY TE: Overexpression of the A9 antigen a6I34 in head and neck cancer. Otolaryngol. Clin. North Am. (1992) 25:1117–1139.
   PubMed Web of Science ®Google Scholar
• BARTOLAZZI A, CERBONI C, FLAMINI G et al: Expression of alpha 3 beta 1 integrin receptor and its ligands in human lung tumors. Int. J. Cancer (1995) 64:248–252.
   PubMed Web of Science ®Google Scholar
• HEBERT M, WASHINGTON R, STEIN J, WEDEMEYER G, GROSSMAN HB: Expression of the VLA pi integrin fam- ily in bladder cancer. Am. J. Pathol (1994) 144:1016–1022.
   PubMed Web of Science ®Google Scholar
• HALL PA, COATES P, LEMOINE NR, HORTON MA: Charcterization of integrin chains in normal and neo- plastic human pancreas. J. Pathol (1991) 165:33–41.
   PubMed Web of Science ®Google Scholar
• BROOKS PC: Cell adhesion molecules in angiogenesis. Cancer Metast. Rev. (1996) 15:187–194.
   PubMed Web of Science ®Google Scholar
• DRAKE CJ, CHERESH DA, LITTLE CD: An antagonist of integrin a5I33 prevents maturation of blood vessels durng embryonic neovascularisation. J. Cell Sci. (1995) 108:2655–2661.
   PubMed Web of Science ®Google Scholar
• KOUKOULIS GK, VIRTANEN I, KORHONEN M et al: Immu- nohistochemical localisation of integrins in the nor-mal, hyperplastic, and neoplastic breast. Correlation with their functions as receptors and cell adhesion molecules. Am. J. Pathol (1991) 139:787–799.
   Google Scholar
• HANBY AM, GILLETT CE, PIGNATELLI M, STAMP GW: Beta 1 and beta 4 integrin expression in methacrin and formalin-fixed material from in situ ductal carcinoma of the breast. J. Pathol (1993) 171:257–262.
   PubMed Web of Science ®Google Scholar
• NIGAM AK, SAVAGE FJ, BOULOS PB et al: Loss of cell-cell and cell-matrix adhesion molecules in colorectal can- cer. Br. J. Cancer (1993) 68:507–514.
   PubMed Web of Science ®Google Scholar
• BONKHOFF H, STEIN U, REMBERGER K: Differential ex- pression of the as and az very late antigen integrins in the normal, hyperplastic, and neoplastic prostate: si-multaneous demonstration of cell surface receptors and their extracellular ligands. Hum. Pathol. (1993) 24:243–249.
   PubMed Web of Science ®Google Scholar
• SEFTOR REB, SEFTOR EA, STETLER-STEVENSON WG, HEN-DRIX MJC: The 72 kDa Type IV collagenase is modulated via differential expression of avP3 and asPi integrins during melanoma cell invasion. Cancer Res. (1993) 53:3411–3415.
   PubMed Web of Science ®Google Scholar
• BROOKS PC, STROMBLAD S, SANDERS LC et al: Localisa- tion of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with a433. Cell (1996) 85:683–693.
   PubMed Web of Science ®Google Scholar
• WILLIAMS AF, BARCLAY AN: The immunoglobulin super- family domains for cell surface recognition. Ann. Rev. Immunol (1988) 6:381–405.
   PubMed Web of Science ®Google Scholar
• CUNNINGHAM BA, HEMPERLY JJ, MURRAY BA et al.: Neu- ral cell adhesion molecule: structure, immunoglobulin-like domains, cell surface modulation and alternative RNA splicing. Science (1987) 236:701–703.
   Google Scholar
• DIACOVO TG, DEFOUGEROLLES AR, BAINTON DF, SPRIN-GER TA: A functional integrin ligand on the surface of platelets: intercellular adhesion molecule-2. J. Clin. In-vest. (1994) 94:1243–1251.
   PubMed Web of Science ®Google Scholar
• RICE GE, GIMBRONE MA, BEVILACQUA MP: Tumour cell- endothelial cell interactions. Increased adhesion of human melanoma cells to activated vascular endothe- lium. Am. J. Pathol (1988) 133:204–210.
   Google Scholar
• THOMPSON JA, GRUNERT F, ZIMMERMANN W: Carel- noembryonic antigen gene family: molecular biology and clinical perspectives. J. Clin. Lab. Anal. (1991) 5:344–366.
   PubMed Web of Science ®Google Scholar
• FEARON ER, CHO KR, NIGRO JM et al: Identification of a chromosome 18q gene that is altered in colorectal cancers. Science (1990) 247:49–56.
   PubMed Web of Science ®Google Scholar
• JOHNSON JP: The role ofICAM-1 in tumor development. Chem. Immunol (1991) 50:143–163.
   PubMed Web of Science ®Google Scholar
• OBIRI NI, TANDON N, PURI RK: Up-regulation of inter- cellular adhesion molecule 1 (ICAM-1) on human renal cell carcinoma cells by interleukin-4. Int. J. Cancer (1995) 61:635–642.
   PubMed Web of Science ®Google Scholar
• SANTAROSA M, FAVARO D, QUAIA M et al.: Expression and release of intercellular adhesion molecule-1 in renal-cancer patients. Int. J. Cancer (1995) 62:271–275.
   PubMed Web of Science ®Google Scholar
• TSUJISAKI M, IMAI K, HIRATA H et al.: Detection of circulating intercellular adhesion molecule-1 antigen in malignant diseases [see comments]. Clin. Exp. Immu-nol. (1991) 85:3–8.
   PubMed Web of Science ®Google Scholar
• PTAH L, FICHTEL A, TERPE HJ, IMHOF BA, GISLER RH:Endothelial vascular cell adhesion molecule-1 expres- sion is suppressed by melanoma and carcinoma. J. Exp. Med. (1995) 181:811–816.
   PubMed Web of Science ®Google Scholar
• MOERTEL G, FLEMING TR, MACDONALD JS et al: An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. J. Am. Merl. Assoc. (1993) 270:943–947.
   PubMed Web of Science ®Google Scholar
• BENCHIMOL S, FUKS A, JOTHY S et al: Carcinoembroynic antigen, a human tumour marker, functions as an intercellular adhesion molecule. Cell (1989) 57:327–334.
   PubMed Web of Science ®Google Scholar
• HASHINO J, FUKUDA Y, OIKAWA S, NAKAZATO H, NAKANISHI T: Metastatic potential of human colorectal carcinoma SW1222 cells transfected with cDNA encod- ing carcinoembryonic antigen. Clin. Exp. Metast. (1994) 12:324–328.
   PubMed Web of Science ®Google Scholar
• LAN KH, KANAI F, SHIRATORI Y et al.: Tumor-specific gene expression in carcinoembryonic antigen-produc- ing gastric cancer cells using adenovirus vectors. Gas-troenterology (1996) 111:1241–1251.
   PubMed Web of Science ®Google Scholar
• ONO T, KOMATSU M, HOSHINO T et al.: Alpha-fetopro- tein, carcinoembryonic antigen, and carbohydrate an- tigen 19-9-producing gallbladder cancer. J. Gastroenterol (1996) 31:742-746. Exp. Opin. Invest. Drugs (1997) 6(10)
   Google Scholar
• ATHANASSIADOU P, PSYHOYOU H, KYRKOU K, ATHA-NASSIADES P, MOULOPOULOS S: Expression of keratins and carcinoembryonic antigen in bronchial squamous metaplasia and lung carcinomas. Acta Cytol. (1995) 39:1161–1166.
   PubMed Web of Science ®Google Scholar
• HOSTETTER RB, CAMPBELL DE, CHI KF et al.: Carcinoem-bryonic antigen enhances metastatic potential of hu-man colorectal carcinoma. Arch. Surg (1990) 125:300–304.
   PubMed Web of Science ®Google Scholar
• HAGA S, WATANABE O, SHIMIZU T et al: The clinical value of tissue carcinoembryonic antigen in breast cancer. Jpn. j Surg. (1991) 21:278–283.
   PubMedGoogle Scholar
• O'BRINK B: C-CAM (cell-CAM 105)-a member of the growing immunoglobulin superfamily of cell adhesion proteins. Bioessays (1991) 13:227–234.
   PubMed Web of Science ®Google Scholar
• CHFUNG PH, CULIC O, QIU Y et al.: The cytoplasmic domain of C-CAM is required for C-CAM-mediated ad-hesion function: studies of a C-CAM transcript contain-ing an unspliced intron. Biochem. J. (1993) 295:427–435.
   PubMed Web of Science ®Google Scholar
• NEUMAIER M, PAULULAT S, CHAN A, MATTHAES P, WAGENER C: Biliary glycoprotein, a potential human cell adhesion molecule, is down-regulated in colorectal carcinomas. Proc. Nat. Acad. Sci. USA (1993) 90:10744–10748.
   PubMed Web of Science ®Google Scholar
• KLEINERMAN DI, TRONCOSO P, UN SH et al: Consistent expression of an epithelial cell adhesion molecule (C-CAM) during human prostate development and loss of expression in prostate cancer: implication as a tumor suppressor. Cancer Res. (1995) 55:1215–1220.
   PubMed Web of Science ®Google Scholar
• HSIEH JT, LUO W, SONG W et al.: Tumor suppressive role of an androgen-regulated epithelial cell adhesion mole-cule (C-CAM) in prostate carcinoma cell revealed by sense and antisense approaches. Cancer Res (1995) 55:190–197.
   PubMed Web of Science ®Google Scholar
• FEARON ER, PIERCEALL WE: The deleted in colorectal cancer (DCC) gene: a candidate tumour suppressor gene encoding a cell surface protein with similarity to neural cell adhesion molecules. Cancer Sun/. (1995) 24:3–17.
   PubMed Web of Science ®Google Scholar
• FEARON ER, EKSTRAND BC, HU G et al.: Studies of the deleted in colorectal cancer gene in normal and neo-plastic tissues. Cold Spring Harbor Symp. Quant. Biol. (1994) 59:637–643.
   PubMedGoogle Scholar
• VESTWEBER D: The selectins and their ligands. Curr. Top Nlicrobiol. Immunol. (1993) 184:65–75.
   PubMedGoogle Scholar
• LAURI D, NEEDHAM L, MARTIN PADURA I, DEJANA E: Tumor cell adhesion to endothelial cells: endothelial leukocyte adhesion molecule-1 as an inducible adhesive receptor specific for colon carcinoma cells. J. Natl. Cancer Inst. (1991) 83:1321–1324.
   PubMed Web of Science ®Google Scholar
• ARUFFO A, DIETSCH M, WAN H, HELLSTROM KE, HELL-STROM I: Granule membrane protein 140 (GMP140) binds to carcinomas and carcinoma-derived cell lines. Proc. Natl. Acad. Sci. USA (1992) 89:2292–2296.
   PubMed Web of Science ®Google Scholar
• SHIMIZU Y, SHAW S: Cell adhesion. Mucins in the main-stream [news; comment]. Nature (1993) 366:630–631.
   Google Scholar
• HILKENS J, LIGTENBERG MJL, VOS HL, LITVINOV SV: Cell membrane-associated mucins and their adhesion modulating property. Trends Biochem. Sci (1992) 17:1066–1070.
   Google Scholar
• ZHANG K, BAECKSTROM D, HANSSON GC: A secreted mucin carrying sialyl-Lewis a from colon carcinoma cells binds to E-selectin and inhibits HL-60 cell adhe-sion. Int. J. Cancer (1994) 59:823–829.
   PubMed Web of Science ®Google Scholar
• REGIMBALD LH, PILARSKI LM, LONGENECKER BM et al.: The breast mucin MUCI as a novel adhesion ligand for endothelial intercellular adhesion molecule 1 in breast cancer. Cancer Res (1996) 56:4244–4249.
   PubMed Web of Science ®Google Scholar
• HANSKI C, HANSKI M-L, ZIMMER T eta].: Characterisation of the major sialyl-Le'-positive mucins present in co-lon, colon carcinoma, and sera of patients with colorec-tal cancer. Cancer Res (1995) 55:928–933.
   Google Scholar
• UNDERHILL C: CD44: the hyaluronan receptor. J. Cell Sci. (1992) 103:293–298.
   PubMed Web of Science ®Google Scholar
• GUNTHERT U: CD44: a multitude of isoforms with di-verse functions. Curr. Top Microbiol. Immunol (1993) 184:47–63.
   PubMedGoogle Scholar
• BOURRGUIGNON LY, IIDA N, WELSH CF et al.: Involve-ment of CD44 and its variant isoforms in membrane-cytoskeleton interaction, cell adhesion and tumor metastasis. J. Neurooncol. (1995) 26:201–208.
   PubMed Web of Science ®Google Scholar
• GUNTHERT U, STAUDER R, MAYER B et al.: Are CD44 variant isoforms involved in human tumour progres-sion? Cancer Surv. (1995) 24:19-42.
   Google Scholar
• PONTA H, SLEEMAN J, DALL P et al.: CD44 isoforms in metastatic cancer. Invasion Metas. (1994) 14:82–86.
   PubMedGoogle Scholar
• TANABE KK, SAYA H: The CD44 adhesion molecule and metastasis. Crit. Rev. Onc. (1994) 5:201–212.
   PubMed Web of Science ®Google Scholar
• GUNTHERT U, HOFMANN M, RUDY W et al: A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell (1991) 65:13–24.
   PubMed Web of Science ®Google Scholar
• DELLAS A, SCHULTHEISS E, ALMENDRAL AC, TORHOST J, GUDAT F: Expression of CD44 and variant isoforms in cervical intraepithelial neoplasia. Gynecol. Oncol (1996) 62:218–225.
   PubMed Web of Science ®Google Scholar
• FINN L, DOUGHERTY G, FINLEY G et al.: Alternative splicing of CD44 pre-mRNA in human colorectal tu-mors. Biochem. Biophys. Res. Commun. (1994) 200:1015–1022.
   PubMed Web of Science ®Google Scholar
• GANSAUGE F, GANSAUGE S, ZOBYWALSKI A et al: Differ-ential expression of CD44 splice variants in human pancreatic adenocarcinoma and in normal pancreas. Cancer Res (1995) 55:5499–5503.
   PubMed Web of Science ®Google Scholar
• HONG RU, LEE WJ, SHUN CT, CHU JS, CHEN YC: Expres-sion of CD44 and its clinical implication in diffuse-type and intestinal-type gastric adenocarcinomas. Oncology (1995) 52:334–339.
   PubMed Web of Science ®Google Scholar
• HUDSON DL, SPEIGHT PM, WATT FM: Altered expression of CD44 isoforms in squamous-cell carcinomas and cell lines derived from them. Int. J. Cancer (1996) 66:457–463.
   PubMed Web of Science ®Google Scholar
• KAN M, FURUKAWA A, AM M, KANAYAMA H, KAGAWA S: Expression of CD44 splice variants in bladder cancer. Int. J. Urol. (1995) 2:295–301.
   PubMedGoogle Scholar
• MANTEN HORST E, DANEN EH, SMIT L et al: Expression of CD44 splice variants in human cutaneous melanoma and melanoma cell lines is related to tumor progression and metastatic potential. Int. J. Cancer (1995) 64:182–188.
   PubMed Web of Science ®Google Scholar
• ARUFFO A. STAMENKOVIC I. MELNICK M. UNDERHILL CB. ARUFFO A, STAMENKOVIC I, MELNICK M, UNDERHILL CB, SEED B: CD44 is the principal cell surface receptor for hyaluronate. Cell (1990) 61:1303–1313.
   PubMed Web of Science ®Google Scholar
• NAGABHUSHAN M, PRETLOW TG, GUO YJ et al.: Altered expression of CD44 in human prostate cancer during progression. Am. J. Clin. Pathol. (1996) 106:647–651.
   PubMed Web of Science ®Google Scholar
• REGIDOR PA, CALLIES R, REGIDOR M et al: Expression of the CD44 variant isoforms 6 and 4/5 in breast cancer. Correlation with established prognostic parameters. Arch. Gynecol Obstet (1996) 258:125–135.
   PubMed Web of Science ®Google Scholar
• BIRCHMEIER W: E-cadherin as a tumor (invasion) sup- pressor gene. Bioessays (1995) 17:97–99.
   PubMed Web of Science ®Google Scholar
• KLEINERMAN DI, ZHANG WW, UN SH et al: Application of a tumor suppressor (C-CAM1)-expressing recombi-nant adenovirus in androgen-independent human prostate cancer therapy: a preclinical study. Cancer Res. (1995) 55:2831–2836.
   PubMed Web of Science ®Google Scholar
• KLEINERMAN DI, DINNEY CP, ZHANG WW et al: Suppres- sion of human bladder cancer growth by increased expression of C-CAM1 gene in an orthotopic model. Cancer Res. (1996) 56:3431–3435.
   PubMed Web of Science ®Google Scholar
• VLEMINCKX K, VAKAET L, JR., MAREEL M, FIERS W, VAN ROY F: Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell (1991) 66:107–119.
   Google Scholar
• MIYAKI M, TANAKA K, KIKUCHI YANOSHITA R et al: Increased cell-substratum adhesion, and decreased ge-latinase secretion and cell growth, induced by E-cad-herin transfection of human colon carcinoma cells. Oncogene (1995) 11:2547–2552.
   PubMed Web of Science ®Google Scholar
• ROSENBERG SA: Development of cancer immunothera- pies based on identification of the genes encoding cancer regression antigens. J. Natl. Cancer Inst. (1996) 88:1635–1644.
   PubMed Web of Science ®Google Scholar
• ADAIR JR: Engineering antibodies for therapy. Immunol Rev (1992) 130:293–299.
   Google Scholar
• RUOSLAHTI E: RGD and other recognition sequences for integrins. Ann. Rev. Cell Dev. Biol. (1996) 12:697–715.
   PubMed Web of Science ®Google Scholar
• BROOKS PC, MONTGOMERY AM, ROSENFELD M et al: Integrin av133 antagonists promote tumour regression by inducing apoptosis of angiogenic blood vessel. Cell (1994) 79:1157–1164.
   PubMed Web of Science ®Google Scholar
• HUMPHRIES MJ, OLDEN K, YAMADA KM: A synthetic peptide from fibronectin inhibits experimental metas- tasis of murine melanoma cells. Science (1986) 233:467–469.
   PubMed Web of Science ®Google Scholar
• MORLA A, ZHANG Z, RUOSLAHTI E: Superfibronectin is a functionally distinct form of fibronectin. Nature (1994) 367:193–196.
   PubMed Web of Science ®Google Scholar
• BROOKS P, STROMBLAD S, KLEMKE R et al: Antiintegrin av133 blocks breast cancer growth and angiogenesis in human skin. J. Clin. Invest. (1995) 96:1815–1822.
   PubMed Web of Science ®Google Scholar
• MOUSA SA: Angiogenesis promoters and inhibitors: potential therapeutic implications. Mol. Med. Today (1996) 2:140–142.
   PubMedGoogle Scholar
• NEWTON SA, REEVES EJ, GRALANICK H et al: Inhibition of experimental metastasis of human breast carcinoma cells in athymic nude mice by anti-a3l31 fibronectin receptor integrin antibodies. Int. J. Oncol (1995) 6:1063–1070.
   PubMed Web of Science ®Google Scholar
• GEHLSEN KR, ARGRAVES WS, PIERSCHBACHER MD, RU-OSLAHTI E: Inhibition of in vitm tumour invasion by Arg-Gly-Asp-containing synthetic peptides. J. Cell Biol. (1988) 110:925–930.
   Google Scholar
• SAIKI I, KIOIKE C, OBATA A et al.: Functional role of sialyl Lewis X and fibronectin-derived RGDS peptide ana-logue on tumour-cell arrest in lung followed by ex- travasation. Int. J. Cancer (1996) 65:833–839.
   PubMed Web of Science ®Google Scholar
• ISOAI A, UENO Y, GIGA-HAMA Y, GOTO H, KUMAGAI H: A novel Arg-Gly-Asp containing peptide specific for platelet aggregation and its effects on tumour metasta-sis: a possible mechanism of RGD peptide-mediated inhibition of tumour metastasis. Cancer Lett. (1992) 65:259–264.
   PubMed Web of Science ®Google Scholar
• KOMAZAWA E, SAIKI I, NISHIKAWA Netal.: Inhibition of tumour metastasis by Arg-Gly-Asp-Ser (RGDS) peptide conjugated with sulfated chitin derivative, SCM-chitin- RGDS. Clin. Exp. Metast (1993) 11:291–482.
   Google Scholar
• FERGUSON TA, MIZUTANI H, KUPPER T: Two integrin- binding peptides abrogate T cell-mediated immune responses in vitro. Proc. Natl. Acad. Sci. USA. (1991) 88:8072–8076.
   PubMed Web of Science ®Google Scholar
• PASQUALINI R, BOURDOULOUS S, KOIVUNEN E, WOODS VU, RUOSLAHTI E: A polymorphic form of fibronectin has antimetastatic effects against multiple tumour types. Nature Med. (1996) 2:1197–1203.
   PubMed Web of Science ®Google Scholar
• HEIDER KH, SPROLL M, SUSANI S et al.: Characterization of a high-affinity monoclonal antibody specific for CD44v6 as candidate for immunotherapy of squamous cell carcinomas. Cancer Immunol Immunother. (1996) 43:245–253.
   PubMed Web of Science ®Google Scholar
• SETTER S, ARCH R, REBER S et al: Prevention of tumour metastasis formation by antivariant CD44. J. Exp. Med (1993) 177:443–455.
   PubMed Web of Science ®Google Scholar
• GUO Y, MA J, WANG J et al.: Inhibition of human melanoma growth and metastasis in vivo by anti-CD44 monoclonal antibody [published erratum appears in Cancer Res. (1994 April 15) 54(8):2284]. Cancer Res (1994) 54:1561–1565.
   Google Scholar
• MUCKENSCHNABEL I, BERNHARDT G, SPRUSS T, BUSCHAUER A: Hyaluronidase pretreatment produces selective melphalan enrichment in malignant mela- noma implanted in nude mice. Cancer Chem other. Phar-macol. (1996) 38:88–94.
   PubMed Web of Science ®Google Scholar
• SPRUSS T, BERNHARDT G, SCHONENBERGER H, SCHIESS W: Hyaluronidase significantly enhances the efficacy of regional vinblastine chemotherapy of malignant mela- noma. J. Cancer Res. Clin. Oncol (1995) 121:193–202.
   PubMed Web of Science ®Google Scholar
• BECKENLEHNER K, BANNKE S, SPRUSS T et al.: Hyaluroni- dase enhances the activity of adriamycin in breast cancer models in vitro and in vivo. J. Cancer Res. Clin. Oncol (1992) 118:591–596.
   Google Scholar
• CROIX BS, RAK JW, KAPITAIN S et al.: Reversal by hyaluronidase of adhesion-dependent multicellular drug resistance in mammary carcinoma cells. J. Natl. Cancer Inst. (1996) 88:1285–1296.
   PubMed Web of Science ®Google Scholar
• KERBEL RS, ST. CROIX B, RAK J, GRAHAM CH: Is there a role for 'anti-adhesives' as chemosensitisers in the treatment of solid tumours by chemotherapy? Bull. L 'Institut Pasteur (1995) 92:248–256.
   Google Scholar
• SARTOR WM, KYPRIANOU N, FABIAN DF, LEFOR AT: Enhanced expression of ICAM-1 in a murine fibrosarcoma reduces tumour growth rate. J. Surg. Res. (1995) 59:66–74.
   PubMed Web of Science ®Google Scholar
• WET K, WILSON JG, JURGENSEN CH et al Xenogeneic ICAM-1 gene tranfer suppresses tumorigenicity and generates protective antitumour immunity. Gene Ther. (1996) 3:531–541.
   PubMed Web of Science ®Google Scholar
• ZANGEMEISTER WITTKE U, COLLINSON AR, FROSCH B et Immunotoxins recognising a new epitope on the neural cell adhesion molecule have potent cytotoxic effects against small cell lung cancer. Br. J. Cancer (1994) 69:32–39.
   PubMed Web of Science ®Google Scholar
• EPSTEIN C, LYNCH T, SHEFNER J eta].: Use of the immu-notoxin N901-blocked ricin in patients with small-cell lung cancer. Int. J. Cancer Suppl (1994) 8:57–59.
   Google Scholar
• ROBBINS PF, EGGENSPERGER D, QI CF: Definition of the expression of the human carcinoembryonic antigen and non-specific cross reacting antigen in human breast and lung carcinomas. mt. I Cancer (1993) 53:892–897.
   PubMed Web of Science ®Google Scholar
• SHARKEY RM, GOLDENBERG DM, GOLDENBERG H eta].: Murine monoclonal antibodies against carcinoem-bryonic antigen: immunological, pharmacokinetic, and targeting properties in humans. Cancer Res. (1990) 50:2823–2831.
   Google Scholar
• BAGSHAVVE KD: The first Bagshawe lecture. Towards generating cytotoxic agents at cancer sites. Br. Cancer (1989) 60:275–281.
   PubMed Web of Science ®Google Scholar
• SHARMA SK, BAGSHAWE KD, BURKE PJ, BODEN RW, ROGERS GT: Inactivation and clearance of an anti-CEA carboxypeptidase G2 conjugate in blood after localisa-tion in a xenograft model. Br. J. Cancer (1990) 61:659–662.
   PubMed Web of Science ®Google Scholar
• MEYER DL, LAW KL, PAYNE JK eta].: Site-specific prodrug activation by antibody-beta-lactamase conjugates: pre-clinical investigation of the efficacy and toxicity of doxorubicin delivered by antibody directed catalysis. Bioconjug. Chem. (1995) 6:440–446.
   Google Scholar
• BAGSHAVVE KD, SHARAM SK, SPRINGER CJ, ANTONIW P: Antibody directed enzyme prodrug therapy: a pilot-scale clinical trial. Tumour Target. (1995) 1:17–29.
   Google Scholar
• KAUFMAN H, SCHLOM J, KANTOR J: A recombinant vaccinia virus expressing human carcinoembryonic antigen (CEA). Int.J. Cancer (1991) 48:900–907.
   PubMed Web of Science ®Google Scholar
• CONRY RM, LOBUGLIO AF, CURIEL DT: Polynucleotide-mediated immunization therapy of cancer. Semin. On-col. (1996) 23:135–147.
   Google Scholar
• HERLYN D, SOMASUNDARAM R, ZALOUDIK J: Anti-idio-type and recombinant antigen in immunotherapy of colorectal cancer. Cell Biophys (1994) 24–25:143–153.
   Google Scholar